AbbVie Inc. (ABBV-N) Stock Predictions - Stockchase
WATCH LIST
36
AbbVie Inc. (ABBV-N)

ON STOCKCHASE SINCE Jan 2013

0

AbbVie Inc.

ABBV-N

45 watching          
Join the Discussion

AbbVie Inc. (ABBV-N) SAVE Nov, 16, 2018, 2:51 pm

91.48 1.34 (1.49%)

About AbbVie Inc. (ABBV-N)

AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories. More at Wikipedia

What the experts are saying about ABBV-N



  • All
  • Filtered
Signal Opinion Expert
BUY
AbbVie Inc.(ABBV-N) 

November 7, 2018

Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row.
0 0 0 0 0
0 comments
Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row.
0
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$86.960
Owned Owned
Yes

HOLD
AbbVie Inc.(ABBV-N) 

September 12, 2018

Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend. 

0 0 0 0 0
0 comments

Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend. 

0
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$93.240
Owned Owned
Yes

WATCH
AbbVie Inc.(ABBV-N) 

August 21, 2018

This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works.

0 0 0 0 0
0 comments

This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works.

0
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$97.740
Owned Owned
Unknown

BUY
AbbVie Inc.(ABBV-N) 

July 5, 2018

Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation. 

0 0 0 0 0
0 comments

Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation. 

0
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$94.480
Owned Owned
Yes

BUY
AbbVie Inc.(ABBV-N) 

June 22, 2018

Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate.

0 0 0 0 0
0 comments

Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate.

0
0 0 0 0 0
0 comments
Greg Newman

Director &, Scotia Wealth Manage...

Price Price
$95.550
Owned Owned
No

DON'T BUY
AbbVie Inc.(ABBV-N) 

April 24, 2018

A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else.

0 0 0 0 0
0 comments

A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else.

0
0 0 0 0 0
0 comments
James Telfser

Partner & , Aventine Management ...

Price Price
$91.360
Owned Owned
No

TOP PICK
AbbVie Inc.(ABBV-N) 

April 12, 2018

A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27)

0 0 0 0 0
0 comments

A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27)

0
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$92.120
Owned Owned
Yes

TOP PICK
AbbVie Inc.(ABBV-N) 

March 23, 2018

He holds this in a pure technical system portfolio.  It was down 13% yesterday and they decided to step in.  A lung cancer drug recently announced disappointing results.  They see health care in a secular bull market.  A hot pick today. 

0 0 0 0 0
0 comments

He holds this in a pure technical system portfolio.  It was down 13% yesterday and they decided to step in.  A lung cancer drug recently announced disappointing results.  They see health care in a secular bull market.  A hot pick today. 

0
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$97.460
Owned Owned
Yes

STRONG BUY
AbbVie Inc.(ABBV-N) 

March 21, 2018

Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it.

0 0 0 0 0
0 comments

Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it.

0
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$112.450
Owned Owned
Yes

COMMENT
AbbVie Inc.(ABBV-N) 

September 19, 2017

(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world.

0 0 0 0 0
0 comments

(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world.

0
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$86.370
Owned Owned
Unknown

BUY
AbbVie Inc.(ABBV-N) 

September 14, 2017

You absolutely have to hold on to it if you have a 2 year outlook.  Humera is the largest selling drug in the world.  They are forever in patent disputes.  They have taken this cash cow and used the proceeds to reinvest in their pipeline.  They have a great balance sheet and a great yield.  We are seeing great results from their trials.  It should have double digit growth and should be at 15 times.  It should consolidate higher than where it is.

0 0 0 0 0
0 comments

You absolutely have to hold on to it if you have a 2 year outlook.  Humera is the largest selling drug in the world.  They are forever in patent disputes.  They have taken this cash cow and used the proceeds to reinvest in their pipeline.  They have a great balance sheet and a great yield.  We are seeing great results from their trials.  It should have double digit growth and should be at 15 times.  It should consolidate higher than where it is.

0
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$89.220
Owned Owned
Unknown

PAST TOP PICK
AbbVie Inc.(ABBV-N) 

August 24, 2017

(Top Pick Jun 23/16, Up 23.30%)  He still likes it and it is one of his favourite healthcare names.  It has a 12 times PE and 8% long time growth rate.  It trades at a discount to its peer group.  Humeria is 60% of their revenues so we have to watch this concentration risk.

0 0 0 0 0
0 comments

(Top Pick Jun 23/16, Up 23.30%)  He still likes it and it is one of his favourite healthcare names.  It has a 12 times PE and 8% long time growth rate.  It trades at a discount to its peer group.  Humeria is 60% of their revenues so we have to watch this concentration risk.

0
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$72.110
Owned Owned
Unknown

DON'T BUY
AbbVie Inc.(ABBV-N) 

June 21, 2017

(Market Call Minute.) The spinoff from Abbott Labs (ABT-N). What makes him hesitate about this is that it is more of a 1 product company with their Humira drug. It represents about 65% of their total revenue, so that presents risks.

0 0 0 0 0
0 comments

(Market Call Minute.) The spinoff from Abbott Labs (ABT-N). What makes him hesitate about this is that it is more of a 1 product company with their Humira drug. It represents about 65% of their total revenue, so that presents risks.

0
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$71.340
Owned Owned
Unknown

COMMENT
AbbVie Inc.(ABBV-N) 

May 10, 2017

This is kind of the by-product of one of these ultra blockbuster drugs. Their anti-inflammatory franchise is the largest selling drug right now. The company has done a good job of building out their pipeline. They have a cancer drug that is expected to be one of the top 10 by 2020. May 17 is a key date for the company as there is a challenge. Trading at 12X earnings, and going down to 10X with the dividend yield under 4%, so he would be cautious until May 17.

0 0 0 0 0
0 comments

This is kind of the by-product of one of these ultra blockbuster drugs. Their anti-inflammatory franchise is the largest selling drug right now. The company has done a good job of building out their pipeline. They have a cancer drug that is expected to be one of the top 10 by 2020. May 17 is a key date for the company as there is a challenge. Trading at 12X earnings, and going down to 10X with the dividend yield under 4%, so he would be cautious until May 17.

0
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$65.980
Owned Owned
Yes

PAST TOP PICK
AbbVie Inc.(ABBV-N) 

April 20, 2017

(A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved.

0 0 0 0 0
0 comments

(A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved.

0
0 0 0 0 0
0 comments
Lorne Zeiler

Portfolio , TriDelta Financial...

Price Price
$63.780
Owned Owned
Yes

Showing 1 to 15 of 36 entries
Successfully Saved Company
Successfully Saved Company